Biocompatibles Settles Charges Of Illegally Selling Device As Drug-Delivery Combo
Executive Summary
The company pleaded guilty to a misdemeanor misbranding charge and agreed to pay $11m in criminal penalties and another $25m to resolve civil False Claims Act allegations. Biocompatibles reportedly marketed its LC Bead product as a drug-delivery product, even though it was cleared only for embolization.
You may also be interested in...
BTG Set To Launch First Radiopaque Drug-Eluting Bead In The EU
DC Bead Lumi is designed to be loaded with doxorubicin or irinotecan to treat liver cancer while showing the treating physician where it is to improve control of transarterial chemoembolization procedures.
BTG Announces Subsidiary Settlement
BTG will pay $36m to the US Department of Justice to resolve claims its subsidiary, Biocompatibles, violated marketing regulations in promoting its LC Bead embolization system between 2003 and 2011.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.